Mandate

Vinge has advised Scandic in connection with its rights issue and the agreement on new credit facilities

Vinge has advised Scandic Hotels Group AB (publ) on a fully underwritten rights issue, which will provide Scandic with issue proceeds amounting up to approximately SEK 1,765 million before deduction of transaction costs, and on the agreement of new credit facilities amounting to SEK 1,400 million.

The new shares are expected to be admitted to trading on Nasdaq Stockholm around 29 June 2020.

With 53,000 hotel rooms in operation at 268 hotels in about 130 locations, Scandic is the leading hotel company in the Nordic region. Most of Scandic’s hotels are operated under the fully-owned Scandic brand, which is the best-known hotel brand in the Nordics.

Scandic is listed on Nasdaq Stockholm, Mid cap.

Vinge’s team primarily consisted of Jesper Schönbeck, David Andersson, Amanda Knutsson, William Kåge, Anders Sundin Lundberg, Eléonore Friberg (Capital markets), Louise Brorsson Salomon, Thomas Sjöberg, Robert Wikholm, Linn Adelwald, Ludvig Wettergren and Elias Lundin (Banking and Finance).

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025